Our meta-analysis suggested that 85% of the patients those underwent EECP therapy improved by at least 1 CCS class immediately post-EECP treatment. The CCS angina class is a relatively minor predictor of prognosis and freedom from events, so our results are noteworthy and the studies evaluated long-term benefit of EECP therapy are warranted. Currently, EECP treatment provides a safe, well-tolerated, valuable option for patients who were unresponsive to maximal medical management and/or invasive therapy. Of note, in combination with other antianginal drugs, the FDA approved Ranolazine to treatment for chronic angina in 2002.

Operation Environment

Ambient temperature: 10°C~30°C;

Relative humidity: less than 85%;

Atmospheric pressure (absolute pressure): 70kPa~106kPa;

Well ventilated and free of dust, corrosive gases and strong electromagnetic interference.

http://www.cneecp.com/